Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Congratulations!
dbrock
Congratulations to Drs. Ivy Franco and Medhavi Gupta!
Author
Denise Brock
Image
Congratulations to two of GRACE's current Patient Education Ambassadors for their recent awards!

Dr. Medhavi Gupta has received the ASCO GI21 Conquer Cancer Foundation Merit Award.  

Dr. Gupta is currently a Hematology-Oncology fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York.  The ASCO GI21 Merit Award recognizes oncology fellows and trainees who are first authors on top-ranking abstracts selected for presentation at the virtual Gastrointestinal Cancers Symposium, 2021.   To read more about Dr. Gupta's study, visit https://meetinglibrary.asco.org/record/194118/abstract.  For information on the ASCO GI21 Award, please see https://www.conquer.org/news/conquer-cancer-announces-2021-gastrointest….

 

Dr. Ivy Franco is the inaugural recipient of the Brigham Womens and Dana Farber Diversity Equity Inclusion Award.

Dr. Idalid “Ivy” Franco is a radiation oncology resident at the Harvard Radiation Oncology Program, in Boston, Massachusetts.  She is the inaugural recipient of the Diversity Equity Inclusion Award with Dana-Farber/Brigham and Women's Cancer Center, awarded for her outstanding contributions towards efforts at diversity, equity and inclusion within the organization and related to the community at large.  

 

Huge congratulations to these two rising stars! GRACE is honored to work along side of you!

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on